Effectiveness of mebeverine in patients with post-cholecystectomy gastrointestinal spasm: results of prospective observational program "odyssey".

AIM: To assess the effectiveness of mebeverine 200 mg BID in patients with post-cholecystectomy gastrointestinal spasm not requiring surgical treatment. MATERIALS AND METHODS: 218 patients were included in 16 clinical centers in 14 cities in Russia. All patients had post-cholecystectomy gastrointestinal spasms, not requiring surgical treatment and received mebeverine (Duspatalin®) 200 mg BID. The observational assessment period lasted from the moment of their inclusion into the study up to 6 weeks post inlusion. The therapy results were evaluated using visual analog scales (GPA and 11-point numeric rating scale) by patient self-assessment of the dynamics of spasm/discomfort and other post-cholecystectomic gastrointestinal symptoms after 2 and 6 weeks of treatment. Gastrointestinal Quality of Life Index (GIQLI) was used to assess patient quality of life. RESULTS: All 218 patients completed the 2-week mebeverine treatment course, 101 of them finished the 6-week course ("prolonged population"). Significant positive changes in the relief of abdominal pain and dyspepsia were noted as well as normalization of stool frequency and consistency. A more marked change in values was observed during prolonged (up to 6 weeks) therapy. Both 2-week and 6-week mebeverine courses led to a normalization of patient quality of life. After 6 week therapy, an effect of mebeverine on the quality of life 91% of patients was observed comparable to cholecystectomy itself, speficially related to the quality of life subscore 'symptoms'. CONCLUSION: The results of our study demonstrate that mebeverine (Duspatalin®) therapy leads to an effective elimination of clinical symptoms associated with post-cholecystectomy GI-spasm disorders, like abdominal pain, symptoms of dyspepsia and stooldisorders. A more marked change in values was observed during prolonged (up to 6 weeks) therapy.

[Effect of phytotherapy on the prevention and elimination of hepatotoxic responses in patients with pulmonary tuberculosis, carriers of hepatitis B virus markers]. / Bliianie fitoterapii na vozmozhnost' preduprezhdeniia i ustraneniia gepatotoksicheskikh reaktsií u bol'nykh tuberkulezom legkikh, nositeleí markerov virusa gepatita B.

Whether hepatotoxic responses (HTR) can be prevented and corrected in patients with pulmonary tuberculosis, carriers of hepatitis B virus markers during specific therapy by using preventive hepatoprotective phytotherapy was studied. Group 1 (n = 54) was given individually chosen plant species infusions having a pronounced heptoprotective effect (liquorice (Glycyrrhiza L.), nettle (Urita L.), tansy (Tanacotum L.), mint (Mentha L.), etc.)) in the whole course of antituberculous treatment. A control group (n = 58) received essentiale, legilon, Liv-52, hemodez from the onset of HTR to their elimination. Phytotherapy was found to reduce to occurrence of HTR by 4.1 times, to eliminate them 2.1 times more rapidly, to shorten the periods of discontinuation of antituberculous agents by 2.1 times, which positively affects the time and efficiency of treatment for tuberculosis.